Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(17 sites) United States
UAB Comprehensive Cancer Center, Birmingham, Alabama Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland Dana-Farber Cancer Institute, Boston, Massachusetts John Theurer Cancer Center at Hackensack UMC, Hackensack, New Jersey Memorial Sloan Kettering Cancer Center, New York, New York Canada
Alberta Health Services AHS - Foothills Medical Centre FMC, Calgary, Alberta University of Alberta - Cross Cancer Institute, Edmonton, Alberta University Health Network UHN - Princess Margaret Hospital PMH, Toronto, Ontario Norway
Oslo University Hospital, Oslo, Outside US and Canada Spain
ICO - Hospital Germans Trias i Pujol, Barcelona Hospital Universitario 12 de Octubre, Madrid Hospital Universitario Marques de Valdecilla, Santander United Kingdom
The Christie NHS Foundation Trust, Manchester, Greater Manchester Local Institution - 0001, Leicester, Leicestershire Local Institution - 0014, Liverpool, Merseyside Churchill Hospital, Oxford, Oxfordshire NIHR UCLH Clinical Research Facility, London